These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 20133383)

  • 1. Investigator-initiated trials of targeted oncology agents: why independent research is at risk?
    Bergmann L; Berns B; Dalgleish AG; von Euler M; Hecht TT; Lappin GL; Reed N; Palmeri S; Smyth J; Embacher-Aichorn S; Zwierzina H;
    Ann Oncol; 2010 Aug; 21(8):1573-1578. PubMed ID: 20133383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective.
    McCabe C; Bergmann L; Bosanquet N; Ellis M; Enzmann H; von Euler M; Jönsson B; Kallen KJ; Newling D; Nüssler V; Paschen B; de Wilde R; Wilking N; Teale C; Zwierzina H;
    Ann Oncol; 2009 Mar; 20(3):403-12. PubMed ID: 18854550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs.
    Hata T; Nakamura K; Yonemori K; Noguchi E; Watanabe M; Sohn J; Lu YS; Yap YS; Tamura K; Fujiwara Y
    Clin Transl Sci; 2021 May; 14(3):1015-1025. PubMed ID: 33382914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pursuit of personalized anticancer therapy: leveraging collaboration between academia and the biotech/pharmaceutical industry.
    Buck E; Mulvihill M; Iwata KK
    Mt Sinai J Med; 2010; 77(4):358-65. PubMed ID: 20687181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer.
    Vassal G; Rousseau R; Blanc P; Moreno L; Bode G; Schwoch S; Schrappe M; Skolnik J; Bergman L; Bradley-Garelik MB; Saha V; Pearson A; Zwierzina H
    Eur J Cancer; 2015 Jan; 51(2):218-24. PubMed ID: 25434924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guidelines, editors, pharma and the biological paradigm shift.
    Singh AR; Singh SA
    Mens Sana Monogr; 2007 Jan; 5(1):27-30. PubMed ID: 22058616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug development and clinical trials--the path to an approved cancer drug.
    Rubin EH; Gilliland DG
    Nat Rev Clin Oncol; 2012 Feb; 9(4):215-22. PubMed ID: 22371130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trials in paediatric oncology. Recommendations for the development of new anticancer agents.
    Vassal G; Méry-Mignard D; Caulin C
    Therapie; 2003; 58(3):229-46. PubMed ID: 14655318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New drugs for children and adolescents with cancer: the need for novel development pathways.
    Vassal G; Zwaan CM; Ashley D; Le Deley MC; Hargrave D; Blanc P; Adamson PC
    Lancet Oncol; 2013 Mar; 14(3):e117-24. PubMed ID: 23434337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
    Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
    Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT).
    Smoragiewicz M; Adjei AA; Calvo E; Tabernero J; Marabelle A; Massard C; Tang J; de Vries EGE; Douillard JY; Seymour L;
    Clin Cancer Res; 2020 Jun; 26(11):2461-2465. PubMed ID: 32086344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted approaches to childhood cancer: progress in drug discovery and development.
    Hirsch S; Marshall LV; Carceller Lechon F; Pearson AD; Moreno L
    Expert Opin Drug Discov; 2015 May; 10(5):483-95. PubMed ID: 25840490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-risk trials for children and pregnant women threatened by unnecessary strict regulations. Does the coming EU Clinical Trial Regulation offer a solution?
    Knaapen M; Ploem MC; Kruijt M; Oudijk MA; van der Graaf R; Bet PM; Bakx R; van Heurn LWE; Gorter RR; van der Lee JH
    Eur J Pediatr; 2020 Aug; 179(8):1205-1211. PubMed ID: 32535715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development.
    Bando H; Takebe N
    Jpn J Clin Oncol; 2015 Nov; 45(11):1001-6. PubMed ID: 26423340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New paradigms for cancer drug discovery.
    Sager JA; Lengauer C
    Cancer Biol Ther; 2003; 2(4):452-5. PubMed ID: 14508120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A program to provide regulatory support for investigator-initiated clinical research.
    Arbit HM; Paller MS
    Acad Med; 2006 Feb; 81(2):146-53. PubMed ID: 16436575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries.
    Wilking N; Bucsics A; Kandolf Sekulovic L; Kobelt G; Laslop A; Makaroff L; Roediger A; Zielinski C
    ESMO Open; 2019; 4(6):e000550. PubMed ID: 31798977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.